Newswire

FDA Warns Against vROX Due to Hidden Drug Ingredient

The Food and Drug Administration (FDA) has issued a warning regarding vROX, a product marketed for sexual enhancement that may contain undisclosed pharmaceutical ingredients. This advisory comes as the FDA has identified that vROX is being sold on various online platforms and potentially in brick-and-mortar retail locations, raising concerns about consumer safety and regulatory compliance.

The presence of hidden drug ingredients in vROX not only poses health risks to users but also highlights ongoing challenges in the regulation of dietary supplements and over-the-counter products. The FDA’s action underscores the importance of vigilance in the marketplace, particularly in sectors where products are often marketed without adequate oversight.

For B2B professionals in the pharmaceutical industry, this situation serves as a critical reminder of the need for stringent quality assurance and regulatory adherence. Ensuring that products are free from harmful substances is essential to maintaining consumer trust and safeguarding public health.

Explore deeper: the API & FDF Intelligence database is more than a directory. It combines global coverage of APIs, excipients, and finished dosage forms with real market intelligence. You’ll find: – Price ranges for APIs, excipients, and formulations. – DMF, CEP, and GMP compliance status. – Manufacturer portfolios by product and geography. – Direct contacts for every producer and FDF holder, ready for outreach. Instead of scattered spreadsheets and endless searches, the entire picture is a few clicks away. Subscription starts at an accessible rate — see how much time and budget you save by centralizing everything.
Start your 7-day trial and see what the database can do →